
Boston Scientific
BSX · NYSE · Health Care
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $64,3 bn
- Div. yield
- —
- Year to date
- −53,5%
Ratio score
based on 9 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
6 ✓ · 3 — · 0 ✕ · 1 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 18,4 | 62,2 | 25,1 |
| Forward P/E | 14,0 | — | 16,2 |
| PEG | 0,7 | — | 2,2 |
| P/S | 3,1 | 5,7 | 2,2 |
| EV/EBITDA | 15,6 | 32,8 | 17,3 |
| P/FCF | 19,3 | — | 19,5 |
| P/B | 2,5 | 4,2 | 3,4 |
Industry median — across 33 profitable companies in “Health Care” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 37 analysts
- Buy
- 24
- Hold
- 12
- Sell
- 1
Beat the EPS forecast in 4 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q3 2026 | 0,72 | 0,73 | Up +0,9% |
| Q2 2026 | 0,84 | 0,86 | Up +2,9% |
| Q1 2026 | 0,79 | 0,80 | Up +0,7% |
| Q4 2025 | 0,79 | 0,80 | Up +1,6% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5,14 bn | 5,44 bn | 5,20 bn | 5,29 bn | 5,07 bn | 5,06 bn | 4,66 bn | 4,56 bn | 4,21 bn | 4,12 bn | 3,86 bn | 3,73 bn |
| EPS | 0,40 | 0,61 | 0,90 | 0,45 | 0,51 | 0,53 | 0,45 | 0,38 | 0,32 | 0,22 | 0,33 | 0,34 |
| Margin | 11,3% | 16,6% | 25,7% | 12,7% | 14,9% | 15,7% | 14,4% | 12,3% | 11,1% | 7,8% | 12,8% | 13,5% |
| FCF | 868 m | 1,28 bn | 171 m | 1,01 bn | 1,16 bn | 1,13 bn | 354 m | 1,18 bn | 823 m | 658 m | −15,0 m | 690 m |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: purchases $10,0 m (5 people), sales $16,8 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| morano susan e25 Aug 2026 · open-market purchase | $100 408 | 2 040 | $49,22 |
| habiger david c5 Aug 2026 · open-market purchase | $99 937 | 2 100 | $47,59 |
| habiger david c4 Aug 2026 · open-market purchase | $6 802 | 140 | $48,59 |
| mahoney michael f3 Aug 2026 · open-market purchase | $9,00 m | 186 240 | $48,33 |
| habiger david c3 Aug 2026 · open-market purchase | $50 084 | 1 042 | $48,07 |
| ludwig edward j31 Jul 2026 · open-market purchase | $227 400 | 5 000 | $45,48 |
| pegus cheryl20 May 2026 · open-market purchase | $99 987 | 1 770 | $56,49 |
| habiger david c20 May 2026 · open-market purchase | $125 819 | 2 250 | $55,92 |
| ludwig edward j20 May 2026 · open-market purchase | $202 914 | 3 580 | $56,68 |
| habiger david c19 May 2026 · open-market purchase | $125 279 | 2 200 | $56,95 |
| mahoney michael f2 Feb 2026 · sale | $14,9 m | 159 701 | $93,49 |
| mahoney michael f2 Feb 2026 · sale | $112 868 | 1 200 | $94,06 |
| butcher arthur c1 Dec 2025 · sale | $1,76 m | 17 313 | $101,55 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Health Care
- Exchange
- NYSE
- Country
- US
- IPO date
- 19 May 1992
- Website
- www.bostonscientific.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
CAHCardinal Health | $283,85 | no score | 35,7 | — | — |
EWEdwards Lifesciences | $107,11 | 56★★★★★★★★would watch | 60,3 | +13,4% | 15,2% |
CORCencora | $356,94 | 83★★★★★★★★★would consider | 19,7 | +5,1% | 0,8% |
BDXBecton Dickinson | $216,47 | 38★★★★★★★would not consider | 51,8 | −2,6% | 4,5% |
IDXXIdexx Laboratories | $700,65 | 83★★★★★★★★★would consider | 47,2 | +11,9% | 25,4% |
Ratio — a score by our methodology, not an investment recommendation.




